Q-omics provides the consensus-scored TMCO6 profile across patient tissues and cancer cell-line models. TMCO6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMCO6 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TMCO6 RNA expression shows 19,184 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where TMCO6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMCO6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMCO6 survival associations across molecular data types. TMCO6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMCO6 RNA expression–survival associations across cancer types. High TMCO6 expression shows unfavorable associations in LGG, UVM and OV, but favorable associations in MESO, BRCA and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for TMCO6 RNA expression.
This table summarizes TMCO6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMCO6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMCO6 shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, KIRP, BLCA and STAD. The KIRC box plot shows higher TMCO6 RNA expression in tumor versus normal tissue (log2 FC = +0.843, t-test p < 0.001).
This table shows molecular features associated with TMCO6 in patient tissues and cancer cell lines. In patient samples, TMCO6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMCO6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
